1. Home
  2. SW vs ILMN Comparison

SW vs ILMN Comparison

Compare SW & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smurfit WestRock plc Ordinary Shares

SW

Smurfit WestRock plc Ordinary Shares

HOLD

Current Price

$38.13

Market Cap

20.2B

Sector

N/A

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$135.32

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SW
ILMN
Founded
1934
1998
Country
Ireland
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.2B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
SW
ILMN
Price
$38.13
$135.32
Analyst Decision
Strong Buy
Hold
Analyst Count
11
16
Target Price
$53.55
$117.31
AVG Volume (30 Days)
5.1M
1.6M
Earning Date
02-11-2026
02-05-2026
Dividend Yield
4.52%
N/A
EPS Growth
109.82
N/A
EPS
1.42
4.46
Revenue
$31,138,000,000.00
$4,288,000,000.00
Revenue This Year
$52.96
N/A
Revenue Next Year
$2.73
$2.24
P/E Ratio
$26.84
$30.34
Revenue Growth
89.50
N/A
52 Week Low
$32.73
$68.70
52 Week High
$56.05
$153.06

Technical Indicators

Market Signals
Indicator
SW
ILMN
Relative Strength Index (RSI) 57.20 62.29
Support Level $37.53 $129.29
Resistance Level $38.35 $138.80
Average True Range (ATR) 0.85 3.96
MACD 0.26 -0.36
Stochastic Oscillator 82.07 71.84

Price Performance

Historical Comparison
SW
ILMN

About SW Smurfit WestRock plc Ordinary Shares

Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: